Karyopharm Therapeutics (KPTI) PT Raised to $11 at Wedbush

Karyopharm Therapeutics (KPTI) PT Raised to $25 at Baird After Xpovio Approval

Baird analyst Michael Ulz raised the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $25.00 (from $15.00) after the FDA approved Xpovio (selinexor) for the treatment of late line (at least four prior therapies) RRMM, with a better-than-expected label (no Black Box).

The analyst... More

Karyopharm Therapeutics (KPTI) PT Raised to $25 at Baird

Baird analyst Michael Ulz raised the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $25.00 (from $15.00) while maintaining a Outperform rating.

Karyopharm Therapeutics (KPTI) PT Raised to $22 at RBC Capital

RBC Capital analyst Brian Abrahams raised the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $22.00 (from $16.00) while maintaining a Outperform rating.

Karyopharm Therapeutics (KPTI) Confirms FDA Approval of XPOVIO (selinexor) for Treatment of Patients with RRMM

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) today announced that the U.S. Food and Drug Administration (FDA) has approved oral XPOVIOTM (selinexor), a nuclear export inhibitor, in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and... More

FDA Confirms Approval of Karyopharm Therapeutics' (KPTI) Xpovio (selinexor) for Multiple Myeloma

Today, the U.S. Food and Drug Administration granted accelerated approval to Karyopharm Therapeutics (NASDAQ: KPTI) Xpovio (selinexor) tablets in combination with the corticosteroid dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is resistant to several other forms of treatment, including at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

While there is no cure for multiple myeloma, there are FDA-approved treatments to target the cancer and slow down the... More

Karyopharm Therapeutics (KPTI) call put ratio 1.1 calls to 1 put with focus on July 7.5 calls and puts

Karyopharm Therapeutics (NASDAQ: KPTI) call put ratio 1.1 calls to 1 put with focus on July 7.5 calls and puts